Project Grant R01DA061799
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$759K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $147,486 to The Trustees of the University of Pennsylvania to conduct research on the role of mu-opioid receptor (MOR)-expressing neurons in the paraventricular nucleus of the thalamus (PVT) in the development of stress-related phenotypes and their influence on opioid self-administration. The key objectives are to: a) determine how susceptible and resilient...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,411,145 to Rowan University from September 30, 2024 to July 31, 2029. The project aims to unravel the neurobiological mechanisms by which the GPR83 receptor and its endogenous ligand PEN interact with the mu-opioid receptor (MOR) in the periaqueductal gray region of the brain. This research seeks to determine if targeting the GPR83 pathway can...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $454,251 to The Trustees of the University of Pennsylvania to develop a novel "released markers of activity" (RMAs) blood-based monitoring system for long-term tracking of neural circuit activity and opioid receptor gene expression changes in mice exposed to opioids. The goal is to better understand the molecular and functional...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This National Institutes of Health National Institute on Drug Abuse Project Grant award of $234,364.35 supports research from March 1, 2021 through August 31, 2022 at clinical practices of the University of Pennsylvania located in Pennsylvania. The research aims to characterize a nociception-active basolateral amygdala to anterior cingulate cortex circuit that contributes to affective-attention pain behaviors, and determine its overlap with endogenous mu opioid receptor systems. The grant also...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...
This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,333,597.00 to Yale University to conduct research on brain kappa opioid receptors in individuals with opioid use disorder (OUD). The key objectives are to: 1) Use PET imaging to compare kappa opioid receptor availability in early abstinent OUD patients versus healthy controls; 2) Explore the links between kappa opioid receptor...